PEN Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 18.82%. Penumbra, Inc.'s return on equity of 13.4% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.

Penumbra, Inc. has a consensus price target of $327.94, signalling upside risk potential of 3.83%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $95.80 which suggests that it could grow by 11.02%. Given that Edwards Lifesciences Corp. has higher upside potential than Penumbra, Inc., analysts believe Edwards Lifesciences Corp. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.229%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Penumbra, Inc.'s net income of $45.9M is lower than Edwards Lifesciences Corp.'s net income of $292.3M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 75.49x while Edwards Lifesciences Corp.'s PE ratio is 36.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 9.28x versus 8.62x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 14.46%. Penumbra, Inc.'s return on equity of 13.4% beat Masimo Corp.'s return on equity of -19.18%.

Penumbra, Inc. has a consensus price target of $327.94, signalling upside risk potential of 3.83%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 37.87%. Given that Masimo Corp. has higher upside potential than Penumbra, Inc., analysts believe Masimo Corp. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Penumbra, Inc.'s net income of $45.9M is lower than Masimo Corp.'s net income of $53.7M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 75.49x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 9.28x versus 4.21x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 26.1%. Penumbra, Inc.'s return on equity of 13.4% beat ResMed, Inc.'s return on equity of 25.6%.

Penumbra, Inc. has a consensus price target of $327.94, signalling upside risk potential of 3.83%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.38%. Given that ResMed, Inc. has higher upside potential than Penumbra, Inc., analysts believe ResMed, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.60 per share. Penumbra, Inc. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. Penumbra, Inc.'s net income of $45.9M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 75.49x while ResMed, Inc.'s PE ratio is 25.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 9.28x versus 6.84x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 11.55%. Penumbra, Inc.'s return on equity of 13.4% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

Penumbra, Inc. has a consensus price target of $327.94, signalling upside risk potential of 3.83%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.04 which suggests that it could grow by 13.09%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Penumbra, Inc., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 1.06% to investors and pays a quarterly dividend of $0.24 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. Penumbra, Inc.'s net income of $45.9M is lower than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 75.49x while Zimmer Biomet Holdings, Inc.'s PE ratio is 22.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 9.28x versus 2.24x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.